We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Steroidogenesis enzyme inhibitors in Cushing's syndrome.
- Authors
Daniel, Eleni; Newell-Price, John D. C.
- Abstract
Steroidogenesis enzyme inhibitors are the mainstay of medical therapy in Cushing's syndrome (CS). Ketoconazole (KTZ) and metyrapone are the most commonly used agents. Although there is considerable experience of their use in individual specialist centres, these drugs have not been rigorously tested in prospective clinical trials. Clinicians face uncertainties and concerns with respect to the safety profile of these agents, and best means to monitor effect. We review steroidogenesis inhibitors in the management of CS, including older agents (KTZ, metyrapone, etomidate and mitotane) and those currently under development (LCI699, non-racemic KTZ), and offer a practical approach for their use in clinical practice.
- Subjects
CUSHING'S syndrome; ENZYME inhibitors; STEROID synthesis; KETOCONAZOLE; METOPIRONE; ETOMIDATE
- Publication
European Journal of Endocrinology, 2015, Vol 172, Issue 6, pR263
- ISSN
0804-4643
- Publication type
Article
- DOI
10.1530/EJE-14-1014